Immunogenicity and protective efficacy of lipopolysaccharides Shigella flexneri 2a with chemically modified lipid A

Lipopolysaccharide (LPS) of S. flexneri 2a is the main target for the formation of human adaptive immune response. However, the use of S. flexneri 2a LPS for preventive vaccination against dysentery, due to its limited express endotoxin effects in humans. Optimization of conditions for chemical treatment of S. flexneri 2a LPS provided the first modified LPS (mLPS), pyrogenicity, which was lower than the native LPS. This paper presents the results of research antibody response and protective efficacy of mLPS in laboratory animals.

Fries L.F., Montemarano A.D., Mallett C.P., Taylor D.N., Hale T.L., Lowell G.H. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infection and immunity. 2001; 69 (7) : 4545-53.

Passwell J.H., Harlev E., Ashkenazi S., Chu C., Miron D., Ramon R. et al. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infection and immunity. 2001; 69 (3): 1351-7.

Passwell J.H., Ashkenzi S., Banet-Levi Y., Ramon-Saraf R., Farzam N., Lerner-Geva L. et al. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine. 2010; 28 (10): 2231-5.

Westphal О., Luderitz, О., Bister, F. Uber die Extraktion von Bakterien mit Phenol-Wasser Z.Naturforsch. 1952; 7 (Teil B): 148-55.

Сергеев В.В., Солодовников, Ю.П., Елкина, С.И., Шустер, Б.Ю. Эффективность энтеральной иммунизации живой дизентерийной вакциной в полевых опытах. Acta. Microbiol. Acad. Sci. Hung. 1976; 22: 6-9.

Государственная фармакопея Российской Федерации. Издательство «Научный центр экспертизы средств медицинского применения». 2008; XII.

Way S.S., Borczuk A.C.,Goldberg M.B. Adaptive immune response to Shigella flexneri 2a cydC in immunocompetent mice and mice lacking immunoglobulin A. Infection and immunity. 1999; 67 (4): 2001-4-.

Харрисон Т.Р. Внутренние болезни. М., «Медицина». 2002: 1165-8.

Hale T.L.,Keren D.F. Pathogenesis and immunology in shigellosis: applications for vaccine development. Current topics in microbiology and immunology. 1992; 180: 117-37.

Noriega F.R., Losonsky G., Lauderbaugh C., Liao F.M., Wang J.Y.,Levine M.M. Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine. Infection and immunity. 1996; 64 (8): 3055-61.

Апарин П.Г. Полисахаридные вакцины против бактериальных кишечных инфекций. Монография. 2004.

Brade H., Opal S.M., Vogel S.N., Morrison D.C. Endotoxin in Helth and Disease. Marcel Dekker, Inc.; 1999.